2016MASCC/ESMO共识建议——高催吐风险化疗恶心呕吐的预防(更新)发布

2016-07-25 癌症支持疗法多国学会(MASCC,Multinational Association of Supportive Care in Cancer)联合欧洲肿瘤内科 Support Care Cancer.

2016年7月,癌症支持疗法多国学会(MASCC)联合欧洲肿瘤内科学会(ESMO)共同发布了高催吐风险化疗恶心呕吐的预防共识建议,文章主要总结了接受高催吐风险化疗的成恶心呕吐的预防建议,共识建议是对2009年止吐剂共识的更新。获取全文:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载)

2016年7月,癌症支持疗法多国学会(MASCC)联合欧洲肿瘤内科学会(ESMO)共同发布了高催吐风险化疗恶心呕吐的预防共识建议,文章主要总结了接受高催吐风险化疗的成恶心呕吐的预防建议,共识建议是对2009年止吐剂共识的更新。


获取全文:

下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024760, encodeId=4b0a2024e60d0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Wed Mar 08 21:05:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938617, encodeId=d61b193861e55, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 02 22:05:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987642, encodeId=755d198e642ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Sep 14 18:05:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280907, encodeId=1109128090ea8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396539, encodeId=b809139653963, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408392, encodeId=f14a140839285, content=<a href='/topic/show?id=b2785288540' target=_blank style='color:#2F92EE;'>#恶心呕吐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52885, encryptionId=b2785288540, topicName=恶心呕吐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89b42741498, createdName=vividelife, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2017-03-08 liuhuangbo
  2. [GetPortalCommentsPageByObjectIdResponse(id=2024760, encodeId=4b0a2024e60d0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Wed Mar 08 21:05:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938617, encodeId=d61b193861e55, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 02 22:05:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987642, encodeId=755d198e642ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Sep 14 18:05:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280907, encodeId=1109128090ea8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396539, encodeId=b809139653963, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408392, encodeId=f14a140839285, content=<a href='/topic/show?id=b2785288540' target=_blank style='color:#2F92EE;'>#恶心呕吐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52885, encryptionId=b2785288540, topicName=恶心呕吐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89b42741498, createdName=vividelife, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2017-05-02 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=2024760, encodeId=4b0a2024e60d0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Wed Mar 08 21:05:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938617, encodeId=d61b193861e55, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 02 22:05:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987642, encodeId=755d198e642ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Sep 14 18:05:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280907, encodeId=1109128090ea8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396539, encodeId=b809139653963, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408392, encodeId=f14a140839285, content=<a href='/topic/show?id=b2785288540' target=_blank style='color:#2F92EE;'>#恶心呕吐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52885, encryptionId=b2785288540, topicName=恶心呕吐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89b42741498, createdName=vividelife, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2016-09-14 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=2024760, encodeId=4b0a2024e60d0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Wed Mar 08 21:05:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938617, encodeId=d61b193861e55, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 02 22:05:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987642, encodeId=755d198e642ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Sep 14 18:05:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280907, encodeId=1109128090ea8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396539, encodeId=b809139653963, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408392, encodeId=f14a140839285, content=<a href='/topic/show?id=b2785288540' target=_blank style='color:#2F92EE;'>#恶心呕吐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52885, encryptionId=b2785288540, topicName=恶心呕吐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89b42741498, createdName=vividelife, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2016-07-27 zhang92560
  5. [GetPortalCommentsPageByObjectIdResponse(id=2024760, encodeId=4b0a2024e60d0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Wed Mar 08 21:05:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938617, encodeId=d61b193861e55, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 02 22:05:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987642, encodeId=755d198e642ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Sep 14 18:05:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280907, encodeId=1109128090ea8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396539, encodeId=b809139653963, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408392, encodeId=f14a140839285, content=<a href='/topic/show?id=b2785288540' target=_blank style='color:#2F92EE;'>#恶心呕吐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52885, encryptionId=b2785288540, topicName=恶心呕吐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89b42741498, createdName=vividelife, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2024760, encodeId=4b0a2024e60d0, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Wed Mar 08 21:05:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938617, encodeId=d61b193861e55, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 02 22:05:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987642, encodeId=755d198e642ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Sep 14 18:05:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280907, encodeId=1109128090ea8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396539, encodeId=b809139653963, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408392, encodeId=f14a140839285, content=<a href='/topic/show?id=b2785288540' target=_blank style='color:#2F92EE;'>#恶心呕吐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52885, encryptionId=b2785288540, topicName=恶心呕吐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89b42741498, createdName=vividelife, createdTime=Wed Jul 27 04:05:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]

相关资讯

啥叫真正的脑洞大开?看这位法国医生发明家的大作!

最近有一位来自法国巴黎萨伯特慈善医院的神经外科医生Alexandre Carpentier,以第一作者的身份在《科学》杂志的子刊《转化医学》上发表了文章,他带领的团队开发了一种超声装置,对15名出现复发性胶质母细胞瘤病人进行了实验装置检测,目的在于突破血脑屏障,帮助化疗药物到达脑部。  所以,什么是血脑屏障呢?我们为什么要打开它?实际上,血脑屏障并不是环绕在大脑四周的「护城墙」

新型“气泡饮品”有望提高癌症化疗效果

新英国牛津大学6月8日宣布,牛津大学与北爱尔兰大学正合作开发一种含有大量氧气泡的“气泡饮品”,用以提高化疗对癌症的治疗效果。先前研究发现,细胞缺氧是一些癌症扩散、治疗效果不理想的重要原因。这是随着肿瘤的生长,血管会不断被扭曲,传输能力变弱,氧气无法正常输送,化疗药物很难抵达肿瘤的中心区域。为了供氧,目前的通行做法是让病人吸入纯氧或将含氧液体直接注射到肿瘤生长部位等,这些做法虽然有效但会带来很大副作

NEJM:Inotuzumab ozogamicin治疗ALL效果显著

急性淋巴细胞白血病患者预后较差,研究进行了一项研究,试图确定inotuzumab ozogamicin与标准治疗相比,能否改善复发或难治性性急性淋巴细胞白血病患者的预后。Inotuzumab ozogamicin是一款抗体-药物偶联物,由一种以CD22为靶点的单克隆抗体与一种细胞毒性药物连接而成,达到靶向抗癌作用。在3期试验中,研究者将难治性或复发性急性淋巴细胞白血病患者随机分为Inotuzuma

NEJM:使用PET-CT来指导晚期霍奇金淋巴瘤的治疗

本研究测试了中期正电子发射体层摄影术(PET-CT)作为晚期霍奇金淋巴瘤患者化疗早期反应的衡量措施以指导患者的治疗。对于新确诊的晚期经典型霍奇金淋巴瘤患者,基线行PET-CT扫描,然后接受两个周期ABVD方案(阿霉素、博莱霉素、长春新碱、氮烯咪胺)化疗,再行中期PET-CT扫描。对PET图像使用5分法进行集中审查。在治疗第3-6周期时,PET结果阴性的患者经过两周期ABVD治疗后随机分为继续ABV

NEJM:奥氮平可显著改善化疗引起的恶心和呕吐的预防治疗

研究人员研究了奥氮平对接受高致吐化疗的患者预防恶心和呕吐的疗效。原始出处:Rudolph M. Navari,Rui Qin,Kathryn J. Ruddy,et al.Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting,NEJM,2016.7.14

JCO:伊立替康+顺铂 vs 紫杉醇+卡铂一线治疗卵巢透明细胞癌(JGOG3017/GCIG 试验III期)

卵巢透明细胞癌(CCC) 是卵巢上皮肿瘤罕见的组织类型,会导致很差的预后。日本妇科肿瘤学组进行了首次III期随机,CCC特定临床试验比较伊立替康+顺铂 (CPT-P) 与紫杉醇+卡铂(TC)对CCC患者的疗效。 667例CCC I期到IV患者被随机分配到在第1、8天接受伊立替康60 mg/m2 ,第15天加用顺铂60 mg/m2 1天(CPT-P 组),每4周化疗一次,共6个周期;或第1天紫